The ADC Cytotoxic Payloads / Warheads market is anticipated to grow at a CAGR of 12.4% till 2030, claims Roots Analysis
With six approved drugs, namely POLIVY™, LUMOXITI™,
BESPONSA®, MYLOTARG™, KADCYLA®, ADCETRIS® and over 300
drugs underdevelopment, antibody drug conjugates (ADCs) have emerged as a
promising class of targeted therapies for various disease indications
Roots Analysis has announced the
addition of “ADC
Cytotoxic Payloads / Warheads: Products and Services Market,
2021-2030”
report to its list of offerings.
Given the fact that
ADCs are highly potent cytotoxic molecules, the manufacturing of ADCs requires elaborate
and advanced technical capabilities and highly potent chemical substances.
Specifically, the multi-step process of production of cytotoxic payloads, which
are complex structures used in ADCs, requires a specially designed and contained
environment, dedicated manufacturing facilities, specialized analytical and
purification techniques, and storage facilities.
To order this 130+ page
report, which features 50+ figures and 15+ tables, please visit
https://www.rootsanalysis.com/reports/adc-cytotoxic-payloads-market.html
Key Market Insights
Over 40 companies claim to offer ADC cytotoxic payloads /warheads for ADCs
Presently, the market is dominated by the presence of large
(501-10,000 employees) and mid-sized companies ( 51-500 employees). It is worth
noting that majority (44%) of the firms engaged in this domain are based in Europe,
followed by North America (28%) and Asia Pacific (28%).
More than 430 patents related to ADC cytotoxic payloads /
warheads have been granted / filed between 2016-2021
A significant
increase has been observed in the number of patent applications filed over the
last few years. Majority (80%) of the patents were filed / granted in North
America; other key regions with significant intellectual capital include
regions of Europe and South Korea
Close to 40 partnerships have been inked among various
industry and non-industry players between 2016 and 2021
Maximum number of
partnerships were established in 2021, indicating a recent rise in the interest
of players engaged in this domain. It is worth highlighting that, majority of
the deals were licensing agreements, representing over 35% of the total number
of partnerships signed in the given time period.
Close to USD 1,100 million
has been invested by both private and public investors, since 2016
Of the total amount invested, over USD 719 million was
raised through venture capital financing, representing over 42% of the overall funding
activity in this domain. Further, 5 instances of private placements were also
reported, wherein players collectively raised more than USD 190 million.
North America and Europe are anticipated to capture larger
share of the market share by 2030
Growth in this domain is anticipated to be primarily driven by
the demand of auristatins and maytansinoids payloads. It is worth
mentioning that ADC cytotoxic payloads / warheads market for microtubule
inhibitors is likely to capture nearly 40% of the total market share by 2030.
To request a sample copy /
brochure of this report, please visit
https://www.rootsanalysis.com/reports/adc-cytotoxic-payloads-market.html
Key Questions Answered
§
Who are the leading players engaged in the development of ADC
cytotoxic payloads / warheads?
§
What kind of partnership models are commonly adopted by
industry stakeholders engaged in the ADC cytotoxic payloads / warheads domain?
§
Which key investors are likely to drive the development
efforts related to ADC cytotoxic payloads / warheads?
§
How has the intellectual property landscape of ADC
cytotoxic payloads / warheads evolved over the years?
§
How is the current and future opportunity likely to be
distributed across key market segments?
The financial
opportunity within the ADC cytotoxic payloads / warheads market has been
analyzed across the following segments:
§
Type of Payload
§
Payload
- Auristatins
- Camptothecin
- Maytansinoids
§
Type of Product
- Commercialized
Products
- Clinical
Products
§
Key Geographical Regions
- North
America
- Europe
- Asia
Pacific
The report features inputs
from eminent industry stakeholder(s), who were very optimistic concerning the growth
of the ADC cytotoxic payloads / warheads market. It includes detailed
transcripts of the discussions held with the senior representatives of the
stakeholder firms.
The report also includes detailed profiles of the companies
(listed below) engaged in developing ADC cytotoxic payloads / warheads;
each profile features an overview of the company, its financial information (if
available), details on its product portfolio, recent developments, and an
informed future outlook.
§
Abzena
§
Levana Biopharma
§
MabPlex
§
NJ Bio
§
Novasep
§
STA Pharmaceuticals
§
Synaffix
For additional details, please visit
https://www.rootsanalysis.com/reports/adc-cytotoxic-payloads-market.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. Antibody
Drug Conjugates Market, 2021-2030
2.
Biologics
Fill / Finish Services Market, 2021-2030
3.
Global
Antibody Purification Services Market, 2021-2030
Contact:
Ben Johnson
+1 (415) 800 3415
Comments
Post a Comment